We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study.
- Authors
Minari, Roberta; Mazzaschi, Giulia; Bordi, Paola; Gnetti, Letizia; Alberti, Giorgia; Altimari, Annalisa; Gruppioni, Elisa; Sperandi, Francesca; Parisi, Claudia; Guaitoli, Giorgia; Bettelli, Stefania; Longo, Lucia; Bertolini, Federica; Pagano, Maria; Bonelli, Candida; Tagliavini, Elena; Nicoli, Davide; Ubiali, Alessandro; Zangrandi, Adriano; Trubini, Serena
- Abstract
<bold>Background: </bold>In advanced epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC) patients whose disease has progressed during treatment with first- and second-generation tyrosine kinase inhibitors (TKIs), liquid biopsy (LB) is routinely used to evaluate the presence of EGFR T790M as an acquired resistance mechanism. The objective of this study was to assess a real-life picture of EGFR T790M detection in LB.<bold>Materials and Methods: </bold>Liquid biopsies performed between June 2016 and October 2018 for advanced EGFR-mutated NSCLC at disease progression during treatment with first- and second-generation TKIs were retrospectively evaluated in 5 Italian centers. Circulating tumor DNA was extracted from plasma and tested with different commercial kits. The detection rate in LBs and the patients' characteristics were correlated.<bold>Results: </bold>We enrolled 120 consecutive patients. The overall T790M detection rate observed using LB was 25.8%. Fifty-four of 89 (60.7%) patients with negative LB results underwent tissue rebiopsy, and 56% were positive for T790M. The overall rate of T790M positivity in the study cohort was 49.2%. LB performed before formal tumor progression according to Response Evaluation Criteria In Solid Tumors criteria was negative for T790M in all patients (n = 21; P = .012). T790M positivity was statistically significantly higher in cases of disease progression at extrathoracic metastatic sites (P = .008) and, specifically, in the case of worsening bone disease (P = .003).<bold>Conclusion: </bold>Our study shows that the detection of T790M-positive patients whose disease progressed during treatment with first- and second-generation TKIs in real life was according to the literature. However, this result was obtained with a specific clinical course (repeat LBs and tissue rebiopsy), thus implying the necessity for multidisciplinary management.
- Publication
Clinical Lung Cancer, 2020, Vol 21, Issue 5, pe464
- ISSN
1525-7304
- Publication type
journal article
- DOI
10.1016/j.cllc.2020.02.021